Paolo Cavazza
Plus aucun poste en cours
Fortune : 11 M $ au 30/04/2024
Profil
Paolo Cavazza worked as a Principal at SciClone Pharmaceuticals LLC.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 30/06/2023 | 76 580 898 ( 13,01% ) | 11 M $ | 30/04/2024 |
Anciens postes connus de Paolo Cavazza
| Sociétés | Poste | Fin |
|---|---|---|
| SCICLONE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
SciClone Pharmaceuticals LLC
 SciClone Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology SciClone Pharmaceuticals LLC was engaged in the development of therapeutic treatment for oncology, infectious diseases, and cardiovascular disorders. It was also offering ZADAXIN for the treatment of hepatitis B, hepatitis C, certain cancers, and used as immune system enhancer, and DC Bead which is used for the novel treatment of liver cancer. The company was founded in 1990 and was headquartered in San Mateo, CA. | Health Technology |
